Thyrocare Technologies Limited

NSEI:THYROCARE Stock Report

Market Cap: ₹52.6b

Thyrocare Technologies Past Earnings Performance

Past criteria checks 3/6

Thyrocare Technologies's earnings have been declining at an average annual rate of -7.1%, while the Healthcare industry saw earnings growing at 22.7% annually. Revenues have been growing at an average rate of 6.4% per year. Thyrocare Technologies's return on equity is 16.8%, and it has net margins of 13.5%.

Key information

-7.1%

Earnings growth rate

-7.2%

EPS growth rate

Healthcare Industry Growth29.4%
Revenue growth rate6.4%
Return on equity16.8%
Net Margin13.5%
Last Earnings Update30 Sep 2024

Recent past performance updates

Statutory Profit Doesn't Reflect How Good Thyrocare Technologies' (NSE:THYROCARE) Earnings Are

Oct 31
Statutory Profit Doesn't Reflect How Good Thyrocare Technologies' (NSE:THYROCARE) Earnings Are

Recent updates

Statutory Profit Doesn't Reflect How Good Thyrocare Technologies' (NSE:THYROCARE) Earnings Are

Oct 31
Statutory Profit Doesn't Reflect How Good Thyrocare Technologies' (NSE:THYROCARE) Earnings Are

Thyrocare Technologies Limited (NSE:THYROCARE) Looks Just Right With A 26% Price Jump

Aug 01
Thyrocare Technologies Limited (NSE:THYROCARE) Looks Just Right With A 26% Price Jump

Thyrocare Technologies Limited (NSE:THYROCARE) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Jul 26
Thyrocare Technologies Limited (NSE:THYROCARE) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

A Look At The Fair Value Of Thyrocare Technologies Limited (NSE:THYROCARE)

Jun 12
A Look At The Fair Value Of Thyrocare Technologies Limited (NSE:THYROCARE)

Getting In Cheap On Thyrocare Technologies Limited (NSE:THYROCARE) Might Be Difficult

Feb 29
Getting In Cheap On Thyrocare Technologies Limited (NSE:THYROCARE) Might Be Difficult

Revenue Miss: Thyrocare Technologies Limited Fell 10.0% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models

Feb 04
Revenue Miss: Thyrocare Technologies Limited Fell 10.0% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models

Here's Why Thyrocare Technologies (NSE:THYROCARE) Can Manage Its Debt Responsibly

Dec 08
Here's Why Thyrocare Technologies (NSE:THYROCARE) Can Manage Its Debt Responsibly

Why Thyrocare Technologies' (NSE:THYROCARE) Shaky Earnings Are Just The Beginning Of Its Problems

Nov 08
Why Thyrocare Technologies' (NSE:THYROCARE) Shaky Earnings Are Just The Beginning Of Its Problems

Thyrocare Technologies (NSE:THYROCARE) Knows How To Allocate Capital Effectively

Mar 23
Thyrocare Technologies (NSE:THYROCARE) Knows How To Allocate Capital Effectively

Thyrocare Technologies Limited (NSE:THYROCARE) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?

Mar 02
Thyrocare Technologies Limited (NSE:THYROCARE) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?

Investors In Thyrocare Technologies Limited (NSE:THYROCARE) Should Consider This, First

Feb 01
Investors In Thyrocare Technologies Limited (NSE:THYROCARE) Should Consider This, First

Investors Who Bought Thyrocare Technologies (NSE:THYROCARE) Shares A Year Ago Are Now Up 81%

Jan 12
Investors Who Bought Thyrocare Technologies (NSE:THYROCARE) Shares A Year Ago Are Now Up 81%

The Chairman & MD of Thyrocare Technologies Limited (NSE:THYROCARE), Velumani Arokiaswamy, Just Bought A Few More Shares

Dec 24
The Chairman & MD of Thyrocare Technologies Limited (NSE:THYROCARE), Velumani Arokiaswamy, Just Bought A Few More Shares

Under The Bonnet, Thyrocare Technologies' (NSE:THYROCARE) Returns Look Impressive

Dec 17
Under The Bonnet, Thyrocare Technologies' (NSE:THYROCARE) Returns Look Impressive

Thyrocare Technologies Limited's (NSE:THYROCARE) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Nov 30
Thyrocare Technologies Limited's (NSE:THYROCARE) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Analyst Forecasts For Thyrocare Technologies Limited (NSE:THYROCARE) Are Surging Higher

Nov 02
Analyst Forecasts For Thyrocare Technologies Limited (NSE:THYROCARE) Are Surging Higher

Earnings Update: Thyrocare Technologies Limited (NSE:THYROCARE) Just Reported And Analysts Are Boosting Their Estimates

Nov 01
Earnings Update: Thyrocare Technologies Limited (NSE:THYROCARE) Just Reported And Analysts Are Boosting Their Estimates

Revenue & Expenses Breakdown

How Thyrocare Technologies makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NSEI:THYROCARE Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 246,2338402090
30 Jun 245,93977600
31 Mar 245,7197082090
31 Dec 235,5356551210
30 Sep 235,4686481210
30 Jun 235,3385991210
31 Mar 235,2676451210
31 Dec 225,214731830
30 Sep 225,108800830
30 Jun 225,5201,423830
31 Mar 225,8891,761830
31 Dec 216,0511,924650
30 Sep 216,2602,032650
30 Jun 216,0301,685730
31 Mar 214,9461,132650
31 Dec 204,503741690
30 Sep 204,178692690
30 Jun 203,79761200
31 Mar 204,343884690
31 Dec 194,3841,0632440
30 Sep 194,2899902440
30 Jun 194,1658922440
31 Mar 194,0398512440
31 Dec 183,9469392370
30 Sep 183,8229532370
30 Jun 183,6639472370
31 Mar 183,5699332370
31 Dec 173,4931,1171250
30 Sep 173,3599941250
30 Jun 173,25875900
31 Mar 173,0454282200
31 Dec 162,8436591200
30 Sep 162,6996011200
30 Jun 162,5355641200
31 Mar 162,4115181200
31 Mar 151,835452690
31 Mar 141,502462570

Quality Earnings: THYROCARE has high quality earnings.

Growing Profit Margin: THYROCARE's current net profit margins (13.5%) are higher than last year (11.9%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: THYROCARE's earnings have declined by 7.1% per year over the past 5 years.

Accelerating Growth: THYROCARE's earnings growth over the past year (29.5%) exceeds its 5-year average (-7.1% per year).

Earnings vs Industry: THYROCARE earnings growth over the past year (29.5%) did not outperform the Healthcare industry 29.6%.


Return on Equity

High ROE: THYROCARE's Return on Equity (16.8%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/19 17:28
End of Day Share Price 2024/12/19 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Thyrocare Technologies Limited is covered by 13 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alka KatiyarBatlivala & Karani Securities India Pvt. Ltd.
Rahul AgarwalCGS International
Kameswari V. S. ChavaliFirstCall Research